Arjang Djamali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1281052/publications.pdf

Version: 2024-02-01

		100601	100535
179	5,825	38	70
papers	citations	h-index	g-index
179	179	179	6883
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Kidney complications following COVID-19 vaccination; a review of the literature. Journal of Nephropharmacology, 2022, 11, e1-e1.	0.2	3
2	Dysregulation of the sensory and regulatory pathways controlling cellular iron metabolism in unilateral obstructive nephropathy. American Journal of Physiology - Renal Physiology, 2022, 322, F89-F103.	1.3	1
3	Risk factors and outcomes of BK viremia among deceased donor kidney transplant recipients based on donor characteristics. Transplant Infectious Disease, 2022, 24, e13768.	0.7	3
4	Factors affecting sensitization following kidney allograft failure. Clinical Transplantation, 2022, 36, e14558.	0.8	3
5	How Should Acute T-cell Mediated Rejection of Kidney Transplants Be Treated: Importance of Follow-up Biopsy. Transplantation Direct, 2022, 8, e1305.	0.8	5
6	Recurrent Podocytopathy after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2022, , CJN.15891221.	2.2	0
7	The Presence of Donor-specific Antibodies Around the Time of Pancreas Graft Biopsy With Rejection Is Associated With an Increased Risk of Graft Failure. Transplantation, 2022, 106, e289-e296.	0.5	3
8	Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. Transplantation, 2021, 105, 436-442.	0.5	3
9	Kidney transplantation for primary glomerulonephritis: Recurrence risk and graft outcomes with related versus unrelated donors. Transplantation Reviews, 2021, 35, 100584.	1.2	O
10	Incidence, risk factors, and outcomes of postâ€transplant erythrocytosis after kidney transplantation. Clinical Transplantation, 2021, 35, e14166.	0.8	7
11	Risk factors for progression from low level BK dnaemia to unfavorable outcomes after BK management via immunosuppressive reduction. Transplant Infectious Disease, 2021, 23, e13561.	0.7	5
12	Post-Transplant CMV Glomerulitis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 957-959.	2.2	3
13	Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation. American Journal of Transplantation, 2021, 21, 1612-1621.	2.6	11
14	Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation. Transplantation, 2021, 105, 648-659.	0.5	22
15	Role of Virus-Specific T Cell Therapy for Cytomegalovirus and BK Infections in Kidney Transplant Recipients. Kidney360, 2021, 2, 905-915.	0.9	8
16	Graft Function Variability and Slope and Kidney Transplantation Outcomes. Kidney International Reports, 2021, 6, 1642-1652.	0.4	2
17	Sodium zirconium cyclosilicate use in kidney transplant recipients. Nephrology Dialysis Transplantation, 2021, 36, 2151-2153.	0.4	2
18	Continuation of Peritoneal Dialysis in Adult Kidney Transplant Recipients With Delayed Graft Function. Kidney International Reports, 2021, 6, 1634-1641.	0.4	6

#	Article	IF	Citations
19	Successful management of Tâ€cell mediated rejection in a recent kidney transplant recipient with COVIDâ€19 associated severe acute respiratory syndrome. Transplant Infectious Disease, 2021, 23, e13598.	0.7	7
20	Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment. Kidney International Reports, 2021, 6, 1397-1401.	0.4	1
21	Outcomes of Delayed Graft Function in Kidney Transplant Recipients Stratified by Histologic Biopsy Findings. Transplantation Proceedings, 2021, 53, 1462-1469.	0.3	10
22	Postâ€kidney transplant serum magnesium exhibits a Uâ€shaped association with subsequent mortality: an observational cohort study. Transplant International, 2021, 34, 1853-1861.	0.8	4
23	Transplant kidney biopsy for proteinuria with stable creatinine: Findings and outcomes. Clinical Transplantation, 2021, 35, e14436.	0.8	6
24	Preâ€transplant bariatric surgery is not associated with an increased risk of infection after kidney transplant. Transplant International, 2021, 34, 1989-1991.	0.8	2
25	Cytomegalovirus nephritis in kidney transplant recipients: Epidemiology and outcomes of an uncommon diagnosis. Transplant Infectious Disease, 2021, 23, e13702.	0.7	5
26	Significance of Asymptomatic Pyelonephritis Found on Kidney Transplant Biopsy. Transplantation Direct, 2021, 7, e764.	0.8	1
27	Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation. Kidney360, 2021, 2, 1998-2009.	0.9	12
28	The clinical value of donor-derived cell-free DNA measurements in kidney transplantation. Transplantation Reviews, 2021, 35, 100649.	1.2	9
29	Association of Human Leukocyte Antigen Mismatches Between Donorâ€recipient And Donorâ€donor in Pancreas after Kidney Transplant Recipients. Transplant International, 2021, , .	0.8	3
30	COVID-19-associated glomerulopathy and high-risk APOL1 genotype; Basis for a two-hit mechanism of injury? A narrative review on recent findings. Journal of Nephropathology, 2021, 10, e11-e11.	0.1	0
31	Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease. Kidney360, 2021, 2, 312-324.	0.9	6
32	Treatment of Chronic Active Antibody-mediated Rejection With Pulse Steroids, IVIG, With or Without Rituximab is Associated With Increased Risk of Pneumonia. Transplantation Direct, 2021, 7, e644.	0.8	3
33	Conversion from Calcineurin Inhibitor– to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 3252-3264.	3.0	41
34	P.131: Persistent Low Blood Pressure After Simultaneous Pancreas and Kidney Transplant Is not Associated With an Increased Risk of Allograft Loss. Transplantation, 2021, 105, S51-S51.	0.5	0
35	New Approaches to Cardiovascular Disease and its Management in Kidney Transplant Recipients. Transplantation, 2021, Publish Ahead of Print, .	0.5	3
36	Kidney transplant outcomes among recipients with postâ€transplant hip or knee joint replacement surgery. Clinical Transplantation, 2021, , e14564.	0.8	2

#	Article	IF	CITATIONS
37	More Than 25 Years of Pancreas Graft Survival After Simultaneous Pancreas and Kidney Transplantation: Experience From the World's Largest Series of Long-term Survivors. Transplantation, 2020, 104, 1287-1293.	0.5	12
38	Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients. Kidney360, 2020, 1, 1407-1418.	0.9	4
39	A Single-Center Assessment of Delayed Graft Function in Recipients of Simultaneous Liver and Kidney Transplant. Progress in Transplantation, 2020, 30, 342-348.	0.4	3
40	Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Injury in Kidney Transplant Recipients During the Time of the Coronavirus Disease 2019 Pandemic. Transplantation Proceedings, 2020, 52, 2592-2595.	0.3	6
41	The care of kidney transplant recipients during a global pandemic: Challenges and strategies for success. Transplantation Reviews, 2020, 34, 100567.	1.2	9
42	Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients. Transplantation, 2020, 104, 2609-2615.	0.5	8
43	Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019. Transplantation Proceedings, 2020, 52, 2659-2662.	0.3	21
44	Donor-specific antibodies in kidney transplantation: the University of Wisconsin experience. Current Opinion in Organ Transplantation, 2020, 25, 543-548.	0.8	2
45	Obesity: An Independent Predictor of Morbidity and Graft Loss after Kidney Transplantation. American Journal of Nephrology, 2020, 51, 615-623.	1.4	14
46	Third-party vessel allografts in kidney and pancreas transplantation: Utilization, de novo DSAs, and outcomes. American Journal of Transplantation, 2020, 20, 3443-3450.	2.6	3
47	Outcomes of simultaneous pancreas and kidney transplants based on preemptive transplant compared to those who were on dialysis before transplant – a retrospective study. Transplant International, 2020, 33, 1106-1115.	0.8	8
48	Prevalence of primary aldosteronism in hypertensive kidney transplant recipients: A crossâ€sectional study. Clinical Transplantation, 2020, 34, e13999.	0.8	4
49	Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients. Transplantation Direct, 2020, 6, e526.	0.8	0
50	Incidence and Outcomes of Significant Weight Changes After Pancreas Transplant Alone. Transplantation Direct, 2020, 6, e539.	0.8	3
51	Polyomavirus and cytomegalovirus infections are risk factors for grafts loss in simultaneous pancreas and kidney transplant. Transplant Infectious Disease, 2020, 22, e13272.	0.7	6
52	Unusually high rates of acute rejection during the COVID-19 pandemic: cause for concern?. Kidney International, 2020, 98, 513-514.	2.6	20
53	Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation. American Journal of Transplantation, 2020, 20, 1513-1526.	2.6	25
54	Delayed kidney graft function in simultaneous pancreas-kidney transplant recipients is associated with early pancreas allograft failure. American Journal of Transplantation, 2020, 20, 2822-2831.	2.6	8

#	Article	IF	CITATIONS
55	Oxidized-ATP Attenuates Kidney Allograft Rejection By Inhibiting T-Cell, B-Cell, and Macrophage Activity. Kidney360, 2020, 1, 106-114.	0.9	1
56	Short-Term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection. Kidney360, 2020, 1, 389-398.	0.9	5
57	Non-obstructive coronary angiogram findings prior to kidney transplantation do not predict post-transplant cardiac events. Clinical Nephrology, 2020, 94, 273-280.	0.4	4
58	Role of novel biomarkers in kidney transplantation. World Journal of Transplantation, 2020, 10, 230-255.	0.6	26
59	Pre-transplant AT1R antibodies and long-term outcomes in kidney transplant recipients with a functioning graft for more than 5 years. Clinical Nephrology, 2020, 94, 245-251.	0.4	2
60	Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation. Clinical Transplantation, 2019, 33, e13452.	0.8	1
61	Cause of End-Stage Renal Disease Is Not a Risk Factor for Cytomegalovirus Infection After Kidney Transplant. Transplantation Proceedings, 2019, 51, 1810-1815.	0.3	5
62	A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. Journal of the American Society of Nephrology: JASN, 2019, 30, 1481-1494.	3.0	67
63	Outcomes after simultaneous kidneyâ€pancreas versus pancreas after kidney transplantation in the current era. Clinical Transplantation, 2019, 33, e13732.	0.8	17
64	<i>Nocardia</i> infection in kidney transplant recipients: A singleâ€center experience. Transplant Infectious Disease, 2019, 21, e13192.	0.7	8
65	Donor-Specific Antibodies in the Absence ofÂRejection Are Not a Risk Factor for Allograft Failure. Kidney International Reports, 2019, 4, 1057-1065.	0.4	29
66	Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation. Transplantation, 2019, 103, 1468-1476.	0.5	29
67	Glomerular C3 Deposition Is an Independent Risk Factor for Allograft Failure in Kidney Transplant Recipients With Transplant Glomerulopathy. Kidney International Reports, 2019, 4, 582-593.	0.4	10
68	Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes. Transplantation, 2019, 103, 1722-1729.	0.5	76
69	Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model. PLoS ONE, 2019, 14, e0211865.	1.1	13
70	The Association of 25-Hydroxyvitamin D Levels with Late Cytomegalovirus Infection in Kidney Transplant Recipients: the Wisconsin Allograft Recipient Database. Transplantation, 2019, 103, 1683-1688.	0.5	7
71	Harald C. Ott: Clinician-scientist, Cardiothoracic Surgeon, Massachusetts General Hospital, Harvard Medical School. Transplantation, 2019, 103, 862-863.	0.5	24
72	Pancreas Retransplant After Pancreas Graft Failure in Simultaneous Pancreas-kidney Transplants Is Associated With Better Kidney Graft Survival. Transplantation Direct, 2019, 5, e473.	0.8	7

#	Article	IF	Citations
73	Hospitalization Trends for Acute Kidney Injury in Kidney Transplant Recipients in the United States, 2004–2014. Transplantation, 2019, 103, 2405-2412.	0.5	5
74	How Should Pancreas Transplant Rejection Be Treated?. Transplantation, 2019, 103, 1928-1934.	0.5	17
75	Sleep disorders: Serious threats among kidney transplant recipients. Transplantation Reviews, 2019, 33, 9-16.	1.2	14
76	Metabolic Acidosis 1 Year Following Kidney Transplantation and Subsequent Cardiovascular Events and Mortality: An Observational Cohort Study. American Journal of Kidney Diseases, 2019, 73, 476-485.	2.1	26
77	Pretransplant transcriptomic signature in peripheral blood predicts early acute rejection. JCI Insight, 2019, 4, .	2.3	26
78	Histopathological characteristics and causes of kidney graft failure in the current era of immunosuppression. World Journal of Transplantation, 2019, 9, 123-133.	0.6	27
79	Risk factors for graft loss in kidney transplant recipients with g3 glomerulitis: A single-center experience. Clinical Nephrology, 2019, 91, 95-100.	0.4	2
80	Which is more nephrotoxic for kidney transplants: <scp>BK</scp> nephropathy or rejection?. Clinical Transplantation, 2018, 32, e13216.	0.8	22
81	Evaluation of renal metabolic response to partial ureteral obstruction with hyperpolarized ¹³ C MRI. NMR in Biomedicine, 2018, 31, e3846.	1.6	16
82	Concurrent biopsies of both grafts in recipients of simultaneous pancreas and kidney demonstrate high rates of discordance for rejection as well as discordance in type of rejection - a retrospective study. Transplant International, 2018, 31, 32-37.	0.8	27
83	Seasonality of mortality and graft failure among kidney transplant recipients in the US - a retrospective study. Transplant International, 2018, 31, 293-301.	0.8	8
84	B-Lymphocyte Stimulator-Deficient Rats Prevent Donor-Specific Antibody Production and Proliferation in Rodent Model. Journal of the American College of Surgeons, 2018, 227, S251.	0.2	0
85	Autologous Mesenchymal Stromal Cells Prevent Transfusion-elicited Sensitization and Upregulate Transitional and Regulatory B Cells. Transplantation Direct, 2018, 4, e387.	0.8	3
86	Pneumocystis jiroveci pneumonia in kidney and simultaneous pancreas kidney transplant recipients in the present era of routine post-transplant prophylaxis: risk factors and outcomes. BMC Nephrology, 2018, 19, 332.	0.8	15
87	The feared five fungal infections in kidney transplant recipients: A singleâ€center 20â€year experience. Clinical Transplantation, 2018, 32, e13289.	0.8	15
88	<scp>BK</scp> viremia is not associated with adverse outcomes in the absence of <scp>BK</scp> nephropathy. Clinical Transplantation, 2018, 32, e13283.	0.8	10
89	Hypertension guidelines: How do they apply to kidney transplant recipients. Transplantation Reviews, 2018, 32, 225-233.	1.2	19
90	Characteristics and Outcomes of Kidney Transplant Recipients with a Functioning Graft for More than 25 Years. Kidney Diseases (Basel, Switzerland), 2018, 4, 255-261.	1.2	14

#	Article	IF	CITATIONS
91	Outcomes in the highest panel reactive antibody recipients of deceased donor kidneys under the new kidney allocation system. Clinical Transplantation, 2017, 31, e12895.	0.8	10
92	Defining the phenotype of antibody-mediated rejection in kidney transplantation: Advances in diagnosis of antibody injury. Transplantation Reviews, 2017, 31, 257-267.	1.2	21
93	Higher Pretransplantation Hemoglobin A1c Is Associated With Greater Risk of Posttransplant Diabetes Mellitus. Kidney International Reports, 2017, 2, 1076-1087.	0.4	8
94	Incidence and Indications for Late Allograft Pancreatectomy While on Continued Immunosuppression. Transplantation, 2017, 101, 2228-2234.	0.5	10
95	Utility of protocol kidney biopsies for de novo donor-specific antibodies. American Journal of Transplantation, 2017, 17, 3210-3218.	2.6	40
96	Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation. Transplantation Direct, 2017, 3, e227.	0.8	34
97	Kidney Transplant Recipients With Primary Membranous Glomerulonephritis Have a Higher Risk of Acute Rejection Compared With Other Primary Glomerulonephritides. Transplantation Direct, 2017, 3, e223.	0.8	6
98	Chronic allograft injury: Mechanisms and potential treatment targets. Transplantation Reviews, 2017, 31, 1-9.	1.2	23
99	A single center kidney transplant experience among ten Caucasian females with end-stage renal disease due to scleroderma. Clinical Nephrology, 2017, 88, 40-44.	0.4	1
100	The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. Nephrology Dialysis Transplantation, 2016, 31, 1746-1753.	0.4	63
101	Nox2 and Cyclosporine-Induced Renal Hypoxia. Transplantation, 2016, 100, 1198-1210.	0.5	9
102	Longitudinal Assessment of Renal Perfusion and Oxygenation in Transplant Donor-Recipient Pairs Using Arterial Spin Labeling and Blood Oxygen Level-Dependent Magnetic Resonance Imaging. Investigative Radiology, 2016, 51, 113-120.	3.5	38
103	Single-Dose Basiliximab Induction in Low-Risk Renal Transplant Recipients. Pharmacotherapy, 2016, 36, 823-829.	1.2	10
104	In Kidney Transplant Recipients With a Positive Virtual Crossmatch, High PRA was Associated With Lower Incidence of Viral Infections. Transplantation, 2016, 100, 655-661.	0.5	12
105	The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation, 2016, 100, 39-53.	0.5	105
106	Is Kidney Transplantation a Better State of CKD? Impact on Diagnosis and Management. Advances in Chronic Kidney Disease, 2016, 23, 287-294.	0.6	23
107	Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet, The, 2016, 388, 983-993.	6.3	148
108	Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Investigative Radiology, 2016, 51, 701-705.	3.5	41

#	Article	IF	Citations
109	Lymphocyte-depleting induction and steroid minimization after kidney transplantation: A review. Nefrologia, 2016, 36, 469-480.	0.2	11
110	Nature, timing, and severity of complications from ultrasound-guided percutaneous renal transplant biopsy. Transplant International, 2016, 29, 167-172.	0.8	68
111	Markers of Endothelial-to-Mesenchymal Transition. Journal of the American Society of Nephrology: JASN, 2016, 27, 324-332.	3.0	33
112	Predictors and outcomes of delayed graft function after living-donor kidney transplantation. Transplant International, 2016, 29, 81-87.	0.8	90
113	Current outcomes of chronic active antibody mediated rejection $\hat{a} \in A$ large single center retrospective review using the updated BANFF 2013 criteria. Human Immunology, 2016, 77, 346-352.	1.2	70
114	The Association Between Renin-Angiotensin System Blockade and Long-term Outcomes in Renal Transplant Recipients. Transplantation, 2016, 100, 1541-1549.	0.5	16
115	Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation $\hat{a}\in$ " A review. Transplantation Reviews, 2016, 30, 85-91.	1.2	32
116	Acute Rejection in 6-Antigen HLA-Matched Kidney Transplant Recipients: Risk Factors and Outcomes from the Wisconsin Allograft Recipient Database (WisARD). Clinical Transplants, 2016, 32, 135-141.	0.2	0
117	Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model. Transplantation, 2015, 99, 1785-1795.	0.5	10
118	Development and Psychometric Testing of a Sexual Concerns Questionnaire for Kidney Transplant Recipients. Journal of Nursing Measurement, 2015, 23, 499-518.	0.2	0
119	C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. Transplantation, 2015, 99, 1151-1155.	0.5	111
120	Renal Function and Transplantation in Liver Disease. Transplantation, 2015, 99, 1756-1764.	0.5	31
121	Older kidney transplant patients experience less antibodyâ€mediated rejection: a retrospective study of patients with mild to moderate sensitization. Clinical Transplantation, 2015, 29, 1090-1097.	0.8	5
122	Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. Journal of Clinical Investigation, 2015, 125, 208-221.	3.9	62
123	Tacrolimus Trough Level at Discharge Predicts Acute Rejection in Moderately Sensitized Renal Transplant Recipients. Transplantation, 2014, 97, 986-991.	0.5	38
124	Sexual concerns among kidney transplant recipients. Clinical Transplantation, 2014, 28, 1294-1302.	0.8	12
125	Antithymocyte Globulin Is Associated With a Lower Incidence of De Novo Donor-Specific Antibodies in Moderately Sensitized Renal Transplant Recipients. Transplantation, 2014, 97, 612-617.	0.5	67
126	Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney International, 2013, 83, 1185-1192.	2.6	33

#	Article	IF	Citations
127	Serum \hat{l}^2 2 -microglobulin at discharge predicts mortality and graft loss following kidney transplantation. Kidney International, 2013, 84, 810-817.	2.6	24
128	Native kidney function following liver transplantation using calcineurin inhibitors: singleâ€eenter analysis with 20Âyears of followâ€up. Clinical Transplantation, 2013, 27, 193-202.	0.8	18
129	Tubular expression of heat-shock protein 27 inhibits fibrogenesis in obstructive nephropathy. Kidney International, 2013, 83, 84-92.	2.6	25
130	MR measures of renal perfusion, oxygen bioavailability and total renal blood flow in a porcine model: noninvasive regional assessment of renal function. Nephrology Dialysis Transplantation, 2012, 27, 128-135.	0.4	19
131	Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis and Tissue Repair, 2012, 5, 7.	3.4	229
132	Serum HSP27 is associated with medullary perfusion in kidney allografts. Journal of Nephrology, 2012, 25, 1075-1080.	0.9	7
133	Contributing factors to complications and surgical success in mouse kidney transplantation. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2012, 38, 395-404.	0.7	3
134	The impact of hepatitis C virus donor and recipient status on longâ€term kidney transplant outcomes: University of Wisconsin experience. Clinical Transplantation, 2012, 26, 684-693.	0.8	37
135	Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: From toxicogenomics to emerging biomarkers. Pharmacological Research, 2011, 64, 25-30.	3.1	17
136	Reproducibility of renal perfusion MR imaging in native and transplanted kidneys using nonâ€contrast arterial spin labeling. Journal of Magnetic Resonance Imaging, 2011, 33, 1414-1421.	1.9	54
137	Comparing Kidney Perfusion Using Noncontrast Arterial Spin Labeling MRI and Microsphere Methods in an Interventional Swine Model. Investigative Radiology, 2011, 46, 124-131.	3.5	47
138	Luminex-Based Desensitization Protocols: The University of Wisconsin Initial Experience. Transplantation, 2011, 92, 12-17.	0.5	40
139	Update on nephrogenic systemic fibrosis: are we making progress?. International Journal of Dermatology, 2011, 50, 659-666.	0.5	22
140	Measurement and comparison of T1 relaxation times in native and transplanted kidney cortex and medulla. Journal of Magnetic Resonance Imaging, 2011, 33, 1241-1247.	1.9	40
141	Arterial spin labeling MRI for assessment of perfusion in native and transplanted kidneys. Magnetic Resonance Imaging, 2011, 29, 74-82.	1.0	79
142	Chronic Kidney Disease Stage Progression in Liver Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1851-1857.	2.2	38
143	Mycophenolic Acid May Delay Allograft Fibrosis by Inhibiting Transforming Growth Factor-β1-Induced Activation of Nox-2 Through the Nuclear Factor-κB Pathway. Transplantation, 2010, 90, 387-393.	0.5	26
144	Pretransplant Donor-Specific Antibodies Detected by Single-Antigen Bead Flow Cytometry Are Associated With Inferior Kidney Transplant Outcomes. Transplantation, 2010, 90, 1079-1084.	0.5	62

#	Article	IF	Citations
145	Blood oxygen level-dependent and perfusion magnetic resonance imaging: detecting differences in oxygen bioavailability and blood flow in transplanted kidneys. Magnetic Resonance Imaging, 2010, 28, 56-64.	1.0	78
146	The Pin 1 inhibitor juglone attenuates kidney fibrogenesis via Pin 1-independent mechanisms in the unilateral ureteral occlusion model. Fibrogenesis and Tissue Repair, 2010, 3, 1.	3.4	44
147	Increase in proteinuria $\>200 mg/g$ after late rejection is associated with poor graft survival. Nephrology Dialysis Transplantation, 2010, 25, 1300-1306.	0.4	14
148	Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile. Kidney International, 2010, 78, S15-S21.	2.6	6
149	One-Year Serum Albumin is an Independent Predictor of Outcomes in Kidney Transplant Recipients. , 2010, 20, 392-397.		17
150	Do statins delay the incidence of ESRD in diabetic patients with moderate CKD?. Journal of Nephrology, 2010, 23, 321-7.	0.9	2
151	Posttransplant anemia: the role of sirolimus. Kidney International, 2009, 76, 376-382.	2.6	27
152	Recurrent Atypical Hemolytic Uremic Syndrome Associated With Factor I Mutation in a Living Related Renal Transplant Recipient. American Journal of Kidney Diseases, 2009, 53, 321-326.	2.1	29
153	Quantitative MR Measures of Intrarenal Perfusion in the Assessment of Transplanted Kidneys. Academic Radiology, 2009, 16, 1077-1085.	1.3	34
154	Fibrogenesis in Kidney Transplantation: Potential Targets for Prevention and Therapy. Transplantation, 2009, 88, 1149-1156.	0.5	34
155	Alemtuzumab Induction and Antibody-Mediated Kidney Rejection After Simultaneous Pancreas-Kidney Transplantation. Transplantation, 2009, 87, 125-132.	0.5	46
156	Left Atrial Volume Is Associated with Inflammation and Atherosclerosis in Patients with Kidney Disease. Echocardiography, 2008, 25, 264-269.	0.3	26
157	Mitral Annular Calcification is Associated with Reduced Left Ventricular Function and Inflammation in Patients with Chronic Kidney Disease. Journal of the American Society of Echocardiography, 2008, 21, 747-750.	1.2	18
158	Antibody-Mediated Rejection of the Kidney after Simultaneous Pancreas-Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2008, 19, 812-824.	3.0	28
159	Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. American Journal of Physiology - Renal Physiology, 2007, 293, F445-F455.	1.3	112
160	BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction. American Journal of Physiology - Renal Physiology, 2007, 292, F513-F522.	1.3	109
161	Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation. Radiology, 2007, 243, 148-157.	3.6	1,273
162	CKD stage-to-stage progression in native and transplant kidney disease. Nephrology Dialysis Transplantation, 2007, 23, 693-700.	0.4	45

#	Article	IF	CITATIONS
163	Alemtuzumab Induction and Recurrence of Glomerular Disease After Kidney Transplantation. Transplantation, 2007, 83, 1429-1434.	0.5	35
164	Disease Progression and Outcomes in Type 1 Diabetic Kidney Transplant Recipients Based on Posttransplantation CKD Staging. American Journal of Kidney Diseases, 2007, 50, 631-640.	2.1	5
165	Drug Insight: maintenance immunosuppression in kidney transplant recipients. Nature Clinical Practice Nephrology, 2006, 2, 688-699.	2.0	54
166	Noninvasive Assessment of Early Kidney Allograft Dysfunction by Blood Oxygen Level-Dependent Magnetic Resonance Imaging. Transplantation, 2006, 82, 621-628.	0.5	67
167	Medical Care of Kidney Transplant Recipients after the First Posttransplant Year. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 623-640.	2.2	81
168	Heat Shock Protein 27 in Chronic Allograft Nephropathy: A Local Stress Response. Transplantation, 2005, 79, 1645-1657.	0.5	44
169	AT1R blockade reduces IFN-l̂³ production in lymphocytes in vivo and in vitro. Kidney International, 2005, 67, 2134-2142.	2.6	28
170	Epithelialâ€toâ€Mesenchymal Transition and Oxidative Stress in Chronic Allograft Nephropathy. American Journal of Transplantation, 2005, 5, 500-509.	2.6	100
171	Assessment of Acute Renal Transplant Rejection with Blood Oxygen Level–Dependent MR Imaging: Initial Experience. Radiology, 2005, 236, 911-919.	3.6	130
172	Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrology Dialysis Transplantation, 2005, 20, 1456-1462.	0.4	54
173	Intrathymic injection of anti-Fas monoclonal antibody prolongs murine non-vascularized cardiac allograft survival. Transplant International, 2004, 17, 301-9.	0.8	2
174	Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney International, 2003, 64, 1800-1807.	2.6	66
175	Outcomes in kidney transplantation. Seminars in Nephrology, 2003, 23, 306-316.	0.6	56
176	Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients 1. Transplantation, 2003, 76, 816-820.	0.5	52
177	LOW DOSE ANTITHYMOCYTE GLOBULINS IN RENAL TRANSPLANTATION. Transplantation, 2000, 69, 799-805.	0.5	57
178	FAS-MEDIATED CYTOTOXICITY IS NOT REQUIRED FOR REJECTION OF MURINE NONVASCULARIZED HETEROTOPIC CARDIAC ALLOGRAFTS1,2,3. Transplantation, 1998, 66, 1793-1801.	0.5	19
179	FAS AND FAS-L MEDIATED CYTOTOXICITY IN ALLOGRAFT REJECTION. Transplantation, 1998, 66, S38.	0.5	0